Get the Stockscreener App
51.62
3.60%
-1.93
After Hours:
51.62
Cg Oncology Inc stock is traded at $51.62, with a volume of 801.63K.
It is down -3.60% in the last 24 hours and down -3.91% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$53.55
Open:
$53.83
24h Volume:
801.63K
Relative Volume:
0.76
Market Cap:
$4.27B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-40.64
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+4.92%
1M Performance:
-3.91%
6M Performance:
+106.89%
1Y Performance:
+84.36%
1-Day Range:
$51.58
$53.95
1-Week Range:
$49.25
$53.95
52-Week Range:
$14.80
$57.88
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
51.62 | 4.42B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology's Creto Launch Could See Headwind From Reimbursement Incentives, RBC Says - marketscreener.com
Why CG Oncology Inc. stock remains on buy listsDay Trade & Free Growth Oriented Trading Recommendations - mfd.ru
Truist Financial Boosts CG Oncology (NASDAQ:CGON) Price Target to $75.00 - MarketBeat
Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts - Benzinga
CG Oncology stock price target raised to $75 from $66 at Truist Securities - Investing.com
CG Oncology stock price target raised to $75 from $66 at Truist Securities By Investing.com - Investing.com India
Candriam S.C.A. Grows Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat
Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)? - Sahm
HC Wainwright Comments on CG Oncology FY2030 Earnings - MarketBeat
Moving Averages: Is CG Oncology Inc impacted by rising rates2025 Market Outlook & Real-Time Stock Price Movement Reports - baoquankhu1.vn
CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Gem With 48.62% Upside Potential - DirectorsTalk Interviews
Bladder Cancer Vaccines Market Poised for Rapid Growth at 21.32% - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology stock hits all-time high at 57.4 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighShould You Buy? - MarketBeat
What Analysts Are Saying About CG Oncology Stock - Benzinga
CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo - GuruFocus
CG Oncology stock hits all-time high at 57.4 USD - Investing.com
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $73 - 富途牛牛
CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Powerhouse with 41.87% Potential Upside - DirectorsTalk Interviews
Portfolio Shifts: Can CG Oncology Inc expand into new marketsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn
Profit Review: What are CG Oncology Incs earnings expectationsChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - Sahm
Investment Review: Can CG Oncology Inc sustain earnings growthEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON) - The Globe and Mail
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Revenue Check: Is CG Oncology Inc stock a hidden gemRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Gainers Report: Is Citigroup Capital XVI Preferred Security stock undervalued right nowEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
CGON: Pivotal data and regulatory milestones position a novel NMIBC therapy for major market expansion - TradingView
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
CG Oncology Expands At-The-Market Equity Offering Capacity - The Globe and Mail
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI
Why CG Oncology Stock Is Suddenly Climbing Higher - TipRanks
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
Travel Stocks: What is the target price for CG Oncology Inc stock2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com Nigeria
Aug Highlights: Will CG Oncology Inc outperform the market in YEARPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com Nigeria
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology files amendment to increase stock offering to $550 million - Investing.com
CG Oncology Files Amendment to Increase Stock Offering - TradingView
Aug Spikes: Is Skeena Resources Limited attractive for institutional investorsDollar Strength & Weekly Top Stock Performers List - baoquankhu1.vn
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Institution Moves: Why analysts upgrade CG Oncology Inc. stockJuly 2025 Fed Impact & AI Enhanced Trading Signals - Bộ Nội Vụ
Truist Securities raises CG Oncology stock price target to $66 on early trial data - Investing.com Canada
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):